Journal
ANESTHESIOLOGY
Volume 125, Issue 1, Pages 237-249Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ALN.0000000000001163
Keywords
-
Categories
Funding
- National Institutes of Health, Bethesda, Maryland [R01-DK097075, R01-HL092188, R01-HL098294, POI-HL114457, R01-HL119837]
- Radboud Centre for Infectious Diseases, Nijmegen, The Netherlands
- Dutch Society of Anesthesiology, Utrecht, The Netherlands
Ask authors/readers for more resources
Hypoxia and immunity are highly intertwined at clinical, cellular, and molecular levels. The prevention of tissue hypoxia and modulation of systemic inflammation are cornerstones of daily practice in the intensive care unit. Potentially, immunologic effects of hypoxia may contribute to outcome and represent possible therapeutic targets. Hypoxia and activation of downstream signaling pathways result in enhanced innate immune responses, aimed to augment pathogen clearance. On the other hand, hypoxia also exerts antiinflammatory and tissue-protective effects in lymphocytes and other tissues. Although human data on the net immunologic effects of hypoxia and pharmacologic modulation of downstream pathways are limited, preclinical data support the concept of tailoring the immune response through modulation of the oxygen status or pharmacologic modulation of hypoxia-signaling pathways in critically ill patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available